Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Textual)

v3.7.0.1
Commitments and Contingencies (Details Textual) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Jan. 09, 2017
May 02, 2016
Nov. 02, 2015
Oct. 08, 2015
Jul. 31, 2017
Jun. 30, 2017
May 31, 2016
Oct. 19, 2015
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Apr. 30, 2016
Jan. 31, 2016
Oct. 31, 2015
Aug. 31, 2015
Loss Contingencies [Line Items]                                
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities             $ 1,000,000                  
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable             750,000                  
Milestone Payment Description               The amended milestone payments are as follows: (i) commencement of Phase III Study for first licensed drug/product within the United States, Europe, China or Japan - $150,000; (ii) submission of the first NDA within the United States - $500,000; and (iii) receipt of first marketing approval for sale of a license product in the United States- $600,000.                
Research and Development Expense, Total                 $ 515,000 $ 105,000 $ 1,199,000 $ 120,000        
Moleculin LLC [Member]                                
Loss Contingencies [Line Items]                                
Payments for Other Fees             $ 306,186                  
MD Anderson [Member]                                
Loss Contingencies [Line Items]                                
Research and Development Expense, Total $ 302,500         $ 202,500                    
MD Anderson [Member] | Subsequent Event [Member]                                
Loss Contingencies [Line Items]                                
Research and Development Expense, Total         $ 100,000                      
Patent and Technology License Agreement [Member]                                
Loss Contingencies [Line Items]                                
Contractual Obligation, Total                         $ 91,186 $ 175,000 $ 125,000  
Payments for Royalties     $ 125,000                          
License Agreement, Maintenance Fee   $ 20,000                            
License Agreement, Maintenance Fee Annual Increase   10,000                            
Payments for Other Fees       $ 300,000                        
License Agreement, Maintenance Fee - Maximum Payable Per Year   $ 100,000                            
Patent and Technology License Agreement [Member] | Servicing Fee payable [Member]                                
Loss Contingencies [Line Items]                                
Contractual Obligation, Due First Anniversary April 2, 2013                               $ 10,000
Contractual Obligation, Due Second Anniversary                               20,000
Contractual Obligation, Due Third Anniversary                               40,000
Contractual Obligation, Due Fourth Anniversary                               60,000
Contractual Obligation, Due Fifth Anniversary                               80,000
Contractual Obligation, Due Sixth Anniversary                               100,000
Patent and Technology License Agreement [Member] | Minimum Annual Royalty [Member]                                
Loss Contingencies [Line Items]                                
Contractual Obligation, Due in Next Fiscal Year, After Product Approval                               200,000
Contractual Obligation, Due in Second Year, After Product Approval                               400,000
Contractual Obligation, Due in Third Year, After Product Approval                               $ 600,000
Patent and Technology License Agreement [Member] | Letter Agreement [Member]                                
Loss Contingencies [Line Items]                                
Payments for Other Fees       $ 691,186